Ординатура / Офтальмология / Английские материалы / Retinal Vascular Disease_Joussen, Gardner, Kirchhof_2007
.pdf
772 Subject Index
Busacca‘s nodule |
|
659 |
|
|
|
– neurodegeneration |
108 |
|
|
– cyclosporine-induced retina |
|
||||||||||||||||||
b-wave amplitude |
452 |
|
|
|
Churg-Strauss syndrome (CSS) 670 |
toxicity |
|
607 |
|
|
|
|
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
ciliary |
|
|
|
|
|
|
|
|
|
cystoid macular edema (CME) |
327, |
|||||||
calcitonin receptor-like receptor |
|
– |
artery occlusion |
715 |
|
|
|
452, 532, 603, 650, 660, 661 |
|
||||||||||||||||||||
|
(CRLR) |
231 |
|
|
|
|
|
|
– body |
167 |
|
|
|
|
|
|
– pseudo-hole |
369 |
|
|
|
||||||||
Candida endophthalmitis |
610 |
|
cilioretinal |
|
|
|
|
|
|
|
cytokine gradient |
32 |
|
|
|
||||||||||||||
candle wax dripping |
651 |
|
|
– anastomosis formation |
456 |
|
|
|
|
|
|
|
|
|
|||||||||||||||
cannabidiol 115 |
|
|
|
|
|
– artery occlusion |
511, 512 |
|
|
daclizamab |
684 |
|
|
|
|
||||||||||||||
capillary |
|
|
|
|
|
|
|
|
|
c-kit |
84 |
|
|
|
|
|
|
|
|
DAG, see diacylglycerol |
|
|
|||||||
– hemangioma |
538, 736, 744 |
|
|
– c-kit+Sca-1+ lineage (KSL) |
79 |
|
daunomycin |
269 |
|
|
|
||||||||||||||||||
– microaneurysm |
303 |
|
|
|
clathrin |
140 |
|
|
|
|
|
|
db/db mice |
306 |
|
|
|
|
|||||||||||
– non-perfusion |
|
593, 622, 660, 676 |
claudin |
109, 146 |
|
|
|
|
|
deep |
|
|
|
|
|
|
|
||||||||||||
carbogen |
515 |
|
|
|
|
|
|
clinically significant macular edema |
– retinal vascular plexus |
32 |
|
||||||||||||||||||
carbonic anhydrase inhibitor |
364 |
|
(CSME) |
222, 293, 355 |
|
|
|
– vascular plexus |
26 |
|
|
|
|||||||||||||||||
cardiovascular risk factor |
444 |
|
CMV retinitis |
620 |
|
|
|
|
delayed choroidal filling 524 |
|
|||||||||||||||||||
carotid |
|
|
|
|
|
|
|
|
|
coagulation |
|
432 |
|
|
|
|
|
deoxyspergualin (NKT-01) |
631 |
|
|||||||||
– |
artery insufficiency |
519 |
|
|
Coat‘s disease |
258, 413, 561, 568, 620, |
dermatomyositis |
676 |
|
|
|
||||||||||||||||||
– |
stenosis |
514 |
|
|
|
|
|
|
|
740, 751, 766 |
|
|
|
|
|
diabetes |
232, 425, 513 |
|
|
|
|||||||||
cataract surgery |
266, 338 |
|
|
– |
differential diagnosis |
563 |
|
|
– mellitus |
|
444, 524 |
|
|
|
|||||||||||||||
– en bloc technique |
339 |
|
|
collagen |
|
|
|
|
|
|
|
|
diabetic |
|
|
|
|
|
|
|
|||||||||
– extracapsulat |
339 |
|
|
|
|
– II |
707 |
|
|
|
|
|
|
|
– macular edema |
210, 235, 318, 548 |
|||||||||||||
– segmentation technique 339 |
|
– IV |
14, 707 |
|
|
|
|
|
– – pegaptanib |
377 |
|
|
|
||||||||||||||||
cathepsin |
87 |
|
|
|
|
|
|
|
color Doppler imaging |
754 |
|
|
– – ranibizumab |
386 |
|
|
|
||||||||||||
caveolin |
140 |
|
|
|
|
|
|
|
combined hamartoma of the retinal pig- |
– retinopathy |
14, 161, 193, 258, 453, |
||||||||||||||||||
cavernoma |
760 |
|
|
|
|
|
|
|
ment epithelium an retina |
741 |
|
532, 609 |
|
|
|
|
|
|
|
||||||||||
cavernous hemangioma |
548, 735, 751, |
commotio retinae (Berlin‘s edema) |
512 |
– – animal model |
303 |
|
|
|
|||||||||||||||||||||
|
760 |
|
|
|
|
|
|
|
|
|
complement factor |
592 |
|
|
|
– – EURODIAB grading system |
294, |
||||||||||||
CCM, see cerebral cavernous malforma- |
computed tomography (CT) |
754 |
|
299, 300 |
|
|
|
|
|
|
|||||||||||||||||||
|
tion |
|
|
|
|
|
|
|
|
|
congenital |
|
|
|
|
|
|
|
– – grading |
291 |
|
|
|
|
|||||
CD4:CD8 ratio |
657, 663 |
|
|
|
– arteriovenous communication |
535 |
– – growth hormone (GH) |
325 |
|
||||||||||||||||||||
CD18 34, 97, 306, 307 |
|
|
|
– |
retinal macrovessel |
538 |
|
|
– – insulin-deficient model |
305 |
|
||||||||||||||||||
CD45 101 |
|
|
|
|
|
|
|
– vascular malformation |
536 |
|
– – nonproliferative 303 |
|
|
||||||||||||||||
CD117 |
84 |
|
|
|
|
|
|
|
cortical blindness |
694 |
|
|
|
|
– – severity scale |
301 |
|
|
|
||||||||||
cell |
|
|
|
|
|
|
|
|
|
corticosteroid |
364, 459, 487, 490, 491, |
– – somatostatin analogues |
324 |
||||||||||||||||
– fusion |
|
82 |
|
|
|
|
|
|
|
|
606, 664, 668, 675 |
|
|
|
|
– – study (DRS) |
|
343 |
|
|
|
||||||||
– recruitment |
76 |
|
|
|
|
|
– systemic |
653 |
|
|
|
|
|
diacylglycerol (DAG) |
66, 318 |
|
|||||||||||||
central |
|
|
|
|
|
|
|
|
|
cotton wool spot |
8, 291, 297, 447, 473, |
DIC, see disseminated intravascular |
|||||||||||||||||
– retinal artery occlusion (CRAO) |
|
|
583, 592, 607 – 609, 629, 660, 669, 688, |
coagulopathy |
|
|
|
|
|
||||||||||||||||||||
|
181, 510, 715 |
|
|
|
|
|
|
|
694, 718 |
|
|
|
|
|
|
|
diminished a-/b-wave amplitude |
524 |
|||||||||||
– retinal vein occlusion (CRVO) |
181, |
COUP-TFII |
45 |
|
|
|
|
|
diode laser |
409 |
|
|
|
|
|||||||||||||||
|
232, 369, 424, 429, 435, 443, 467, 670, |
COX-1/2, see cyclooxygenase-2 |
|
disseminated intravascular coagulopa- |
|||||||||||||||||||||||||
|
716 |
|
|
|
|
|
|
|
|
|
CRAO, see central retinal artery occlu- |
thy (DIC) |
602, 604, 692, 693 |
|
|||||||||||||||
– – classification |
450 |
|
|
|
|
|
sion |
|
|
|
|
|
|
|
|
drainage service |
277 |
|
|
|
|||||||||
– – precipitating causes |
446 |
|
|
C-reactive protein (CRP) |
514 |
|
dye laser |
229 |
|
|
|
|
|
||||||||||||||||
– serous chorioretinopathy (CSCR) |
CRLR, see calcitonin receptor-like |
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
|
609 |
|
|
|
|
|
|
|
|
|
|
receptor |
|
|
|
|
|
|
|
EAE, see experimental autoimmune |
|||||||||
– serous retinopathy |
235 |
|
|
CRVO, see central retinal vein occlusion |
encephalomyelitis |
|
|
|
|||||||||||||||||||||
cerebral cavernous malformation |
|
cryocoagulation 409, 410 |
|
|
|
Eales‘ disease |
532, 613, 676, 724 |
||||||||||||||||||||||
|
(CCM) |
760 |
|
|
|
|
|
|
CRYO-ROP study |
258 |
|
|
|
|
Early Treatment of Diabetic Retinopathy |
||||||||||||||
– |
differential diagnosis |
763 |
|
|
cryotherapy |
|
256, 392, 421, 564, 739, |
Study (ETDRS) |
99, 233, 292, 320 |
||||||||||||||||||||
– |
genetic loci |
763 |
|
|
|
|
|
755, 766 |
|
|
|
|
|
|
|
early vitrectomy |
267 |
|
|
|
|||||||||
chemokine |
48 |
|
|
|
|
|
|
– panretinal |
277 |
|
|
|
|
|
eclampsia |
691 |
|
|
|
|
|
||||||||
chlorambucil |
683 |
|
|
|
|
|
– vasoproliferative retinal tumor |
766 |
EGF, see epidermal growth factor |
||||||||||||||||||||
chloroquine |
18, 633 |
|
|
|
|
CSCR, see central serous chorioretino- |
EIBOS 261 |
|
|
|
|
|
|
||||||||||||||||
chlorpromazine |
280 |
|
|
|
|
|
pathy |
|
|
|
|
|
|
|
|
electroporation |
|
179 |
|
|
|
||||||||
chorioretinal venous anastomosis |
460 |
CSME, see clinically significant macular |
electroretinogram (ERG) |
513 |
|
||||||||||||||||||||||||
choroid |
167 |
|
|
|
|
|
|
|
|
edema |
|
|
|
|
|
|
|
|
Elschnig‘s spot |
694 |
|
|
|
||||||
choroidal |
|
|
|
|
|
|
|
|
CSMT, see standardized change in mac- |
embolus |
507, 511 |
|
|
|
|||||||||||||||
– granuloma |
662 |
|
|
|
|
|
|
ular thickness |
|
|
|
|
|
endarterectomy |
|
525 |
|
|
|
||||||||||
– hemangioma |
248 |
|
|
|
|
cyclocryocoagulation |
497 |
|
|
|
endocryocoagulation |
257 |
|
|
|||||||||||||||
– hemorrhage |
602, 603 |
|
|
|
cyclohexadiene ring 244 |
|
|
|
endolaser coagulation |
266, 277 |
|
||||||||||||||||||
– melanoma |
751 |
|
|
|
|
|
cyclooxygenase |
|
|
|
|
|
endophthalmitis |
160, 283, 382, 610 |
|||||||||||||||
– neovascularization (CNV) |
55, 240, |
– -1 (COX-1) |
98 |
|
|
|
|
|
– non-infectious |
287 |
|
|
|
||||||||||||||||
|
241, 245, 544, 661, 706, 725, 742 |
|
– |
-2 (COX-2) |
98, 307 |
|
|
|
|
endothelial |
|
|
|
|
|
|
|||||||||||||
choroidopathy |
|
607 |
|
|
|
|
– |
inhibitor |
364 |
|
|
|
|
|
– cell (EC) |
25, 38, 75, 78 |
|
|
|||||||||||
chromovitrectomy |
262 |
|
|
|
cyclophosphamide |
664, 668, 682 |
|
– – proliferation |
703 |
|
|
|
|||||||||||||||||
chronic |
|
|
|
|
|
|
|
|
|
cyclosporine |
|
606 |
|
|
|
|
|
– – survival |
82 |
|
|
|
|
||||||
– constipation |
613 |
|
|
|
|
– A (CSA) |
643, 645, 679 |
|
|
|
– nitric oxide synthase |
378 |
|
||||||||||||||||
Subject Index 773
– |
progenitor cell (EPC) 40, 183 |
fibronectin 14 |
hard exudate 296, 582 |
|
endothelin (ET) 131 |
fibrovascular membrane 330, 338, 403, |
HbSC |
705, 723, 731 |
|
– |
-1 11, 143 |
405 |
HbSS |
700, 705 |
eosinophilic vasculitis 670 |
filopodial-like process |
31 |
HbSThal 705 |
|
eph system 73 |
final visual acuity (FVA) |
454 |
HCRVO, see hemicentral retinal vein |
|
ephrin |
51, 73 |
FLA 469 |
|
occlusion |
epidermal growth factor (EGF) 46 |
Flk-1, see fetal liver kinase |
heavy silicon oil Densiron 264 |
||
epiretinal membrane (ERM) 214, 218, |
Flt-1, see fms-like tyrosine kinase 1 42 |
Heerfordt‘s syndrome 658 |
||
598, 621, 726, 741 |
fluorescein 193 |
|
Heidelberg retina flowmeter (HRF) |
|
epistaxis |
613 |
– angiography (FA) 154, 193, 208, 234, |
168 |
|
ERG, see electroretinogram |
|
244, 250, 347, 359, 448, 451, 469, 471, |
HELLP syndrome |
|
692 |
|
|
||||||||||||||||||||
ERM, see epiretinal membrane |
|
479, 675, 753 |
|
|
|
|
|
|
hemangioblast |
|
|
|
|
|
|||||||||||||
erythema nodosum |
635 |
|
|
– – during pregnancy |
696 |
|
|
– differentiation |
41 |
|
|
||||||||||||||||
erythrocyte sedimentation rate (ESR) |
– leakage |
245 |
|
|
|
|
|
|
– precursor |
41 |
|
|
|
|
|||||||||||||
514 |
|
|
|
|
|
|
|
flux |
|
|
|
|
|
|
|
|
|
hemangioblastoma |
749 |
|
|
||||||
erythropoietin |
48, 98 |
|
|
– paracellular |
140 |
|
|
|
|
hemangioma |
|
|
|
|
|
|
|||||||||||
E-selectin |
705 |
|
|
|
– transcellular |
140 |
|
|
|
|
– |
capillary |
376, 744, 749 |
|
|
||||||||||||
ESR, see erythrocyte sedimentation rate |
fms-like tyrosine kinase 1 (Flt-1) |
42 |
– |
cavernous |
736, 751, 760 |
|
|
||||||||||||||||||||
ET, see endothelin |
|
|
|
focal necrotizing arteritis |
668 |
|
– |
racemose |
743, 751 |
|
|
||||||||||||||||
etanercept |
|
99, 309, 644, 685 |
|
foreign body giant cell |
766 |
|
|
hematopoietic |
|
|
|
|
|
|
|||||||||||||
– protocol |
|
350 |
|
|
|
FOXC2 |
45 |
|
|
|
|
|
|
|
|
– cells |
24, 25 |
|
|
|
|
|
|||||
ETDRS, see Early Treatment of Diabetic |
frequency-doubled Nd:YLF laser |
235 |
– progenitor cells |
|
606 |
|
|
||||||||||||||||||||
Retinopathy Study |
|
|
|
frizzled-4 (Fz4) |
186 |
|
|
|
|
– |
stem cell (HSC) |
|
44, 183 |
|
|
||||||||||||
EURODIAB grading system 293, 299 |
frosted branch angiitis |
676 |
|
|
– – in vascular development |
78 |
|
||||||||||||||||||||
EVR1 |
570 |
|
|
|
|
|
5-FU |
269 |
|
|
|
|
|
|
|
|
hematoporphyrin |
|
244 |
|
|
||||||
experimental autoimmune encephalo- |
fusiform aneurysm |
547 |
|
|
|
hemicentral retinal vein occlusion |
|
||||||||||||||||||||
myelitis (EA) |
650 |
|
|
|
FVL, see factor V Leiden |
|
|
|
|
(HCRVO) |
468 |
|
|
|
|
||||||||||||
expression efficiency |
175 |
|
Fz4, see frizzled-4 |
|
|
|
|
|
hemodilution |
|
458 |
|
|
|
|||||||||||||
extracapsular cataract surgery |
339 |
|
|
|
|
|
|
|
|
|
|
hemoglobin |
240 |
|
|
|
|
||||||||||
extramacular degeneration, age-related |
gadolinium diethylenetriamine-penta- |
– |
S 705 |
|
|
|
|
|
|
|
|||||||||||||||||
751 |
|
|
|
|
|
|
|
acetic acid (Gd-DTPA) |
156 |
|
hemoglobinopathy |
700, 712, 713 |
|
||||||||||||||
exudation |
530, 583, 660 |
|
|
galactosemia |
14 |
|
|
|
|
|
hemorrhage |
291, 583, 629 |
|
|
|||||||||||||
exudative |
|
|
|
|
|
|
gap junction |
5 |
|
|
|
|
|
|
– ARMD |
548 |
|
|
|
|
|
||||||
– retinal detachment |
582, 583, 739, 767 |
gas-compression vitrectomy |
159 |
|
– |
choroidal |
603 |
|
|
|
|
||||||||||||||||
– retinopathy |
545, 549 |
|
|
G-CSF, see granulocyte colony-stimulat- |
– |
cysts |
595 |
|
|
|
|
|
|
||||||||||||||
– vitreoretinopathy |
724, 751 |
|
ing factor |
|
|
|
|
|
|
|
|
– |
intraocular |
|
597 |
|
|
|
|||||||||
Eye Disease Case-Control Study |
483 |
Gd-DTPA, see gadolinium diethylenetri- |
– intraretinal |
|
608, 660, 675, 694 |
|
|||||||||||||||||||||
|
|
|
|
|
|
|
|
amine-pentaacetic acid |
|
|
|
– macular cyst |
596 |
|
|
||||||||||||
FA, see fluorescein angiography |
|
gene |
|
|
|
|
|
|
|
|
|
– premacular |
|
551 |
|
|
|
||||||||||
Fabry‘s disease |
14 |
|
|
|
– mutation |
|
175 |
|
|
|
|
|
– |
preretinal |
550 |
|
|
|
|||||||||
factor V Leiden (FVL) |
425, 432, 637 |
– therapy |
175 |
|
|
|
|
|
|
– retinopathy |
|
443 |
|
|
|
||||||||||||
falciform |
|
|
|
|
|
|
– transfer |
175 |
|
|
|
|
|
|
– Salmon patch |
|
706 |
|
|
||||||||
– retinal detachment |
578 |
|
– – non-viral |
170 |
|
|
|
|
|
– subarachnoid |
|
595 |
|
|
|||||||||||||
– tractional detachment |
573 |
|
genetically engineered virus |
175 |
|
– subdural |
595 |
|
|
|
|
||||||||||||||||
familial exudative vitreoretinopathy |
gestational age |
403, 404 |
|
|
|
– |
subhyaloidal |
610 |
|
|
|||||||||||||||||
(FEVR) |
258, 413, 567, 724, 751 |
GFAP, see fibrillary acidic protein |
|
– |
submacular |
|
551 |
|
|
|
|||||||||||||||||
– differential diagnosis 574 |
|
GH, see growth hormone |
|
|
|
– |
vitreous |
595, 609, 613, 652, 708, |
|||||||||||||||||||
– falciform detachment |
578 |
|
giant cell arteritis |
509 |
|
|
|
|
|
727, 763 |
|
|
|
|
|
|
|
||||||||||
– laser photocoagulation |
576 |
|
glaucoma |
133, 218, 413, 439, 445, 484, |
hemosiderin-laden macrophage |
706, |
|||||||||||||||||||||
– vitrectomy |
577 |
|
|
|
663 |
|
|
|
|
|
|
|
|
|
|
717 |
|
|
|
|
|
|
|
|
|||
– X-linked recessive form |
570 |
|
– Ahmed valve |
278 |
|
|
|
|
heparan sulfate proteoglycan |
707 |
|||||||||||||||||
Fas ligand |
|
357, 636 |
|
|
|
– rubeotic secondary |
274 |
|
|
hepatocyte growth factor (HGF) |
48 |
||||||||||||||||
Fas/FasL |
103, 307 |
|
|
|
glial cell ingrowth |
726 |
|
|
|
|
heterozygous thrombophilic disorder |
||||||||||||||||
Fas-L-mediated apoptosis |
34 |
|
glomerulonephritis |
688 |
|
|
|
|
481 |
|
|
|
|
|
|
|
|
||||||||||
feeder vessel |
373, 762 |
|
|
glutamate |
114, 133 |
|
|
|
|
HGF, see hepatocyte growth factor |
|||||||||||||||||
– photocoagulation |
715 |
|
|
Goodpasture syndrome |
|
673 |
|
|
HIF-1, see hypoxia-inducible factor-1 |
||||||||||||||||||
fenestration |
378 |
|
|
|
gradient index of refraction (GRIN) |
HLA |
|
|
|
|
|
|
|
|
|||||||||||||
fetal liver kinase 1 (Flk-1) |
41 |
|
494 |
|
|
|
|
|
|
|
|
|
– |
B27 |
684 |
|
|
|
|
|
|
||||||
FEVR, see familial exudative vitreoreti- |
graft versus host disease (GVHD) |
606 |
– B51 |
638 |
|
|
|
|
|
|
|||||||||||||||||
nopathy |
|
|
|
|
|
|
granulocyte colony-stimulating factor |
homing |
81 |
|
|
|
|
|
|
||||||||||||
FGF |
68 |
|
|
|
|
|
|
(G-CSF) |
|
83 |
|
|
|
|
|
|
homocysteine |
|
425, 426 |
|
|
||||||
FGF, see fibroblast growth factor |
|
grid pattern |
362 |
|
|
|
|
|
homocystinuria |
|
14 |
|
|
||||||||||||||
fibrillary acidic protein (GFAP) |
114 |
growth hormone (GH) |
325 |
|
|
homonymous hemianopia 539 |
|
||||||||||||||||||||
fibrinolytic |
|
|
|
|
|
GVHD, see graft versus host disease |
HRE, see hypoxia-response element |
||||||||||||||||||||
– agent 495 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HRF, see Heidelberg retina flowmeter |
||||||||||||
– system |
710 |
|
|
|
|
hairpin loop |
700 |
|
|
|
|
|
HSC, see hematopoietic stem cell |
|
|||||||||||||
fibroblast growth factor (FGF) |
30, 68, |
hamartoma |
|
741 |
|
|
|
|
|
hyaloidal vessel |
27 |
|
|
||||||||||||||
123, 231 |
|
|
|
|
|
|
– astrocytic |
751 |
|
|
|
|
|
hyaloidotomy |
|
556 |
|
|
|
||||||||
774 Subject Index
hydroxychloroquine |
628, 633 |
|
– IL-4 |
129 |
|
|
|
|
|
lentivirus |
177 |
|
|
|
|
|
|
||||||||||||||
hyperbaric oxygen |
515 |
|
|
– IL-6 |
98 |
|
|
|
|
|
|
leptin |
48 |
|
|
|
|
|
|
|
|
||||||||||
hypercholesterolemia |
425, 507, 508 |
– |
IL-8 |
83, 636 |
|
|
|
|
|
leucovorin |
681 |
|
|
|
|
|
|
||||||||||||||
hyperfluorescence |
203, 479 |
|
intermediate uveitis |
653, 740 |
leukocyte |
710 |
|
|
|
|
|
|
|||||||||||||||||||
hyperglycemia |
307, 318 |
|
|
intraocular |
|
|
|
|
|
|
lidocaine |
286 |
|
|
|
|
|
|
|||||||||||||
hyperlipidemia |
14, 471 |
|
|
– hemorrhage |
597 |
|
|
|
lipoprotein A |
438 |
|
|
|
|
|
||||||||||||||||
hyperoxia |
171, 395 |
|
|
|
|
– |
pressure (IOP) |
167, 275, 439 |
lisinopril |
310 |
|
|
|
|
|
|
|||||||||||||||
hypertension |
425, 444, 507, 508, 513 |
intraretinal |
|
|
|
|
|
|
Löfgren‘s syndrome |
658 |
|
|
|
||||||||||||||||||
– pregnancy-induced |
691 |
|
– edema |
209 |
|
|
|
|
|
low-coherence interferometry |
206 |
||||||||||||||||||||
hypertensive retinopathy |
210, 453, |
– hemorrhage |
608, 660, 675, 694 |
LRP5 570 |
|
|
|
|
|
|
|
|
|||||||||||||||||||
|
630, 688 |
|
|
|
|
|
|
– microvascular abnormality (IRMA) |
lupus anticoagulant |
430, 481 |
|
|
|||||||||||||||||||
hyperviscosity |
444 |
|
|
|
|
|
16, 233, 291, 298, 324, 303, 707 |
lymphangiogenesis |
40 |
|
|
|
|
||||||||||||||||||
hypofluorescence |
203, 246 |
|
intravascular fibrin clot |
|
604 |
lymphatic system |
38 |
|
|
|
|
||||||||||||||||||||
hypoxia |
131, 709 |
|
|
|
|
intravitreal triamcinolone acetonide |
macroaneurysm |
744, 751 |
|
|
|
||||||||||||||||||||
– hypoxia-induced vascular prolifera- |
|
(IVTA) |
216 |
|
|
|
|
|
|
|
|
||||||||||||||||||||
|
tion |
393 |
|
|
|
|
|
|
– injection |
491 |
|
|
|
|
macrophage |
53, 706, 766 |
|
|
|
||||||||||||
– hypoxia-inducible factor-1 (HIF-1) |
intussusceptive growth |
46 |
– |
migration inhibitory factor (MIF) |
|||||||||||||||||||||||||||
– – |
|
4, 122, 123 |
|
|
|
|
IOP, see intraocular pressure |
|
98 |
|
|
|
|
|
|
|
|
|
|||||||||||||
– – |
|
122 |
|
|
|
|
|
|
iridectomy |
413 |
|
|
|
|
Macugen |
69 |
|
|
|
|
|
|
|
||||||||
– – pathway 121 |
|
|
|
|
iridescent spot |
706 |
|
|
|
macula hole |
512 |
|
|
|
|
|
|
||||||||||||||
– |
hypoxia-inducible factor-2 (HIF-2) |
iris |
167 |
|
|
|
|
|
|
macular |
|
|
|
|
|
|
|
|
|
||||||||||||
– – |
|
46 |
|
|
|
|
|
|
|
– |
neovascularization |
89, 510, 516 |
– |
degeneration, age-related |
751 |
|
|||||||||||||||
– hypoxia-response element (HRE) 125 |
– nodule |
659 |
|
|
|
|
|
– edema |
9, 70, 337, 461, 583, 608, |
||||||||||||||||||||||
hypoxic insult |
12 |
|
|
|
|
IRMA, see intraretinal microvascular |
|
675, 767 |
|
|
|
|
|
|
|
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
abnormality |
|
|
|
|
|
– – clinically significant (CSME) |
355 |
||||||||||||
ICAM-1, see intercellular adhesion mol- |
Irvine-Gass syndrome |
369 |
– – inflammation |
354 |
|
|
|
|
|||||||||||||||||||||||
|
ecule-1 |
|
|
|
|
|
|
|
ischemia |
110, 444, 583, 607, 709 |
– |
grid laser coagulation |
486, 487 |
||||||||||||||||||
idiopathic juxtafoveolar retinal telangi- |
ischemic |
|
|
|
|
|
|
|
– |
hole |
544, 726 |
|
|
|
|
|
|
||||||||||||||
|
ectasis |
210, 252, 528 |
|
|
– index |
451 |
|
|
|
|
|
– pucker |
256 |
|
|
|
|
|
|
||||||||||||
IGF-1, see insulin-like growth factor-1 |
– |
optic neuropathy |
|
669 |
|
– |
scar |
448 |
|
|
|
|
|
|
|
||||||||||||||||
IGFBP-3, see insulin-like growth factor- |
– |
retinopathy |
609 |
|
|
|
– |
star |
690 |
|
|
|
|
|
|
|
|||||||||||||||
|
binding protein-3 |
|
|
|
|
isoniazid |
622 |
|
|
|
|
|
magnetic resonance imaging (MRI) |
||||||||||||||||||
immune-complex deposit |
630 |
|
isovolemic hemodilution |
456, 459 |
|
155, 754 |
|
|
|
|
|
|
|
|
|||||||||||||||||
immunohistochemistry |
116 |
|
IVTA, see intravitreal triamcinolone |
MAGUK, see membrane-associated |
|||||||||||||||||||||||||||
in vitro experiment |
182 |
|
|
|
acetonide |
|
|
|
|
|
|
guanylate kinase |
|
|
|
|
|
||||||||||||||
indocyanine green angiography |
753 |
|
|
|
|
|
|
|
|
|
|
mannose-binding lectin gene-2 |
|
||||||||||||||||||
inflammation in Eales‘ disease |
613 |
JAM, see junction adhesion molecule |
|
(MBL2) |
639 |
|
|
|
|
|
|
||||||||||||||||||||
infliximab |
99, 644, 653, 664, 684 |
junction adhesion molecule (JAM) |
MAPC, see multipotent adult progeni- |
||||||||||||||||||||||||||||
inner limiting membrane (ILM) |
331, |
|
144 |
|
|
|
|
|
|
|
|
tor cell |
|
|
|
|
|
|
|
|
|||||||||||
|
367, 578, 761 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MAP-kinase, see mitogen-activated |
||||||||||||||
– peeling |
353, 369 |
|
|
|
|
Kawasaki disease |
668 |
|
|
|
protein kinase |
|
|
|
|
|
|
||||||||||||||
inner plexiform layer |
111 |
|
|
kinase insert domain-containing recep- |
MARINA Trial |
387 |
|
|
|
|
|
||||||||||||||||||||
Ins2Akita diabetic mice |
112 |
|
|
tor-1 (KD/flk-1) |
232 |
|
masquerade syndrome |
543 |
|
|
|||||||||||||||||||||
insulin |
357 |
|
|
|
|
|
|
Koeppe‘s nodule |
659 |
|
|
matrix metalloproteinase |
357, 378 |
||||||||||||||||||
– resistance |
305 |
|
|
|
|
krypton laser 229 |
|
|
|
|
MBL2, see mannose-binding lectin |
||||||||||||||||||||
– – type-2 diabetes |
305 |
|
|
KSL, see c-kit+Sca-1+ lineage |
|
gene-2 |
|
|
|
|
|
|
|
|
|||||||||||||||||
insulin-deficient model |
305 |
|
|
|
|
|
|
|
|
|
|
|
mean |
|
|
|
|
|
|
|
|
|
|||||||||
insulin-like growth factor |
|
|
lack claudin-5 |
147 |
|
|
|
– |
corpuscular hemoglobin concentra- |
||||||||||||||||||||||
– -1 (IGF-1) |
30, 47, 324, 325, 326, 392, |
lactate |
11 |
|
|
|
|
|
|
|
tion (MCHC) |
714 |
|
|
|
|
|
||||||||||||||
|
396, 397 |
|
|
|
|
|
|
laser |
353 |
|
|
|
|
|
|
– flow velocity (MFV) |
170 |
|
|
||||||||||||
– – brain development |
399 |
|
– ablation |
419 |
|
|
|
|
|
– retinal circulation time (MRCT) |
|||||||||||||||||||||
– binding protein-3 (IGFBP-3) |
86 |
– coagulation |
242, 360 |
|
|
168, 319 |
|
|
|
|
|
|
|
|
|||||||||||||||||
integrin |
|
|
|
|
|
|
|
– Doppler flowmetry |
|
168 |
media opacity |
330 |
|
|
|
|
|
||||||||||||||
– integrin-mediated adhesion |
83 |
– Doppler velocimetry |
168 |
melanin |
240 |
|
|
|
|
|
|
|
|||||||||||||||||||
– |
4 |
1 (VLA-4) |
705 |
|
|
|
– flare photometry |
|
256 |
|
meloxicam |
309 |
|
|
|
|
|
|
|||||||||||||
– |
v |
3/5 |
48 |
|
|
|
|
|
|
– hyaloidotomy |
550 |
|
|
membrane-associated guanylate kinase |
|||||||||||||||||
intercellular adhesion molecule-1 |
– laser-induced chorioretinal venous |
|
(MAGUK) |
147 |
|
|
|
|
|
||||||||||||||||||||||
|
(ICAM-1) |
34, 97, 129, 143, 305 – 307, |
|
anastomosis |
490 |
|
|
|
metalloprotease 9 (MMP-9) |
84 |
|
||||||||||||||||||||
|
639, 705 |
|
|
|
|
|
|
– |
photocoagulation |
377, 392, 576, 654, |
methotrexate |
606, 622, 653, 664, 681 |
|||||||||||||||||||
interfacial surface tension |
264 |
|
|
725, 739, 755 |
|
|
|
|
|
methylenetetrahydrofolate reductase |
|||||||||||||||||||||
interferon (IFN) |
653, 684 |
|
|
leakage |
203, 476 |
|
|
|
|
|
(MTHFR) |
427 |
|
|
|
|
|
||||||||||||||
– IFN- |
|
643 |
|
|
|
|
|
|
leakiness |
26 |
|
|
|
|
|
Meyer-Schwickerath |
228 |
|
|
|
|||||||||||
– IFN- |
|
650 |
|
|
|
|
|
|
Leber‘s miliary aneurysm |
532, 561, |
microaneurysm |
292, 303, 386, 489, |
|||||||||||||||||||
– IFN- |
|
129 |
|
|
|
|
|
|
|
735 |
|
|
|
|
|
|
|
|
530, 608, 609, 621 |
|
|
|
|
|
|||||||
interleukin (IL) |
|
|
|
|
|
lensectomy |
413 |
|
|
|
|
microscopic polyangiitis (MPA) |
668 |
||||||||||||||||||
– IL-1 |
|
|
|
|
|
|
|
|
– lensectomy-vitrectomy-membrane |
microvasculature repair |
13 |
|
|
||||||||||||||||||
– – 1 |
m |
231 |
|
|
|
|
|
|
|
peeling |
421 |
|
|
|
|
|
MIF, see migration inhibitory factor |
||||||||||||||
– – |
|
47, 107, 129, 705 |
|
|
|
lens-sparing vitrectomy |
|
419 |
migration inhibitory factor (MIF) |
98 |
|||||||||||||||||||||
Subject Index 775
mitogen-activated protein kinase (MAP- |
occlusive |
|
|
|
|
|
|
|
|
– liquid (PFCL) |
262, 331 |
|
|
|||||||||||||||
kinase) |
|
66 |
|
|
|
|
|
|
|
– retinopathy |
607 |
|
|
|
|
perfluorodecalin |
262 |
|
|
|
||||||||
monocyte |
54, 99 |
|
|
|
|
|
– vasculitis |
|
|
653 |
|
|
|
|
perfluorooctane |
262 |
|
|
|
|||||||||
– lineage cells |
378 |
|
|
|
|
OCT, see ocular coherence tomography |
peribulbar anesthesia |
348 |
|
|
||||||||||||||||||
mouse model of RPO 393 |
|
|
|
octreotide |
326, 327, 664 |
|
|
pericyte 16, 26, 304 |
|
|
|
|
||||||||||||||||
MPA, see microscopic polyangiitis |
– treatment recommendations |
328 |
peripheral fibrovascular mass |
568 |
||||||||||||||||||||||||
MRCT, see mean retinal circulation time |
ocular |
|
|
|
|
|
|
|
|
periphlebitis |
613, 621, 651 |
|
|
|||||||||||||||
MRI, see magnetic resonance imaging |
– coherence tomography (OCT) |
155, |
perivascular |
|
|
|
|
|
|
|||||||||||||||||||
MS, see multiple sclerosis |
|
|
|
294, 370, 380, 387, 480, 753, 762 |
– mesenchymal cell |
75 |
|
|
||||||||||||||||||||
MTFR, see methylenetetrahydrofolate |
– – Fourier domain |
|
206 |
|
|
– sheathing |
630 |
|
|
|
|
|||||||||||||||||
reductase |
|
|
|
|
|
|
|
|
– – hardware |
|
222 |
|
|
|
|
perivasculitis |
20 |
|
|
|
|
|||||||
Müller cells |
29, 67, 114, 395 |
|
– – software |
|
|
223 |
|
|
|
|
perivenous |
|
|
|
|
|
|
|
||||||||||
multifocal chorioretinitis |
661 |
|
– – title domain |
206 |
|
|
|
– exudation |
660 |
|
|
|
|
|||||||||||||||
multiple sclerosis (MS) |
650 |
|
|
– ischemia |
|
453 |
|
|
|
|
– sheathing |
660 |
|
|
|
|
||||||||||||
multipotent adult progenitor cell |
|
– ischemic syndrome |
519, 521, 609 |
persistent |
|
|
|
|
|
|
|
|||||||||||||||||
(MAPC) |
43 |
|
|
|
|
|
|
– neovascularization |
78, 88 |
|
– fetal vitreous (PHPV) 576 |
|
||||||||||||||||
multi-targeted receptor tyrosine kinase |
oculocerebral |
|
|
|
|
|
|
– hyperplastic primary vitreous |
||||||||||||||||||||
inhibitor (RTKI) |
54 |
|
|
|
|
– lymphoma |
653 |
|
|
|
|
(PHPV) |
413 |
|
|
|
|
|
||||||||||
mural cells |
25 |
|
|
|
|
|
|
– syndrome |
|
535 |
|
|
|
|
PFCL, see perfluorocarbon liquid |
|||||||||||||
Mycobacterium tuberculosis |
613 |
open sky vitrectomy |
|
422 |
|
|
P-glycoprotein 141 |
|
|
|
|
|||||||||||||||||
mycophenolate mofetil |
632, 653, 664, |
optic |
|
|
|
|
|
|
|
|
|
pheochromocytoma |
|
688 |
|
|
||||||||||||
682 |
|
|
|
|
|
|
|
|
|
|
– disk |
|
|
|
|
|
|
|
|
photocoagulation |
345, 755 |
|
|
|||||
myopia |
|
412 |
|
|
|
|
|
|
|
– – drusen |
|
509 |
|
|
|
|
|
– panretinal |
346 |
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
– – edema |
688, 689 |
|
|
|
– protocol |
348 |
|
|
|
|
|
||||||
Nd:YAG laser |
229, 555 |
|
|
|
|
– – swelling |
|
|
592 |
|
|
|
|
– scattered lesions |
346 |
|
|
|||||||||||
Ndpy/– mutant mice |
188 |
|
|
|
– nerve damage |
663 |
|
|
photodisruption |
240 |
|
|
|
|||||||||||||||
necrotizing |
|
|
|
|
|
|
|
|
– neuritis (ON) |
651 |
|
|
|
photodynamic |
|
|
|
|
|
|||||||||
– enterocolitis (NEC) |
397 |
|
|
– neuropathy |
607 |
|
|
|
|
– therapy (PDT) |
239, 583, 755, 766 |
|||||||||||||||||
– vasculitis |
668 |
|
|
|
|
|
|
optical coherence tomography (OCT) |
– – vasoproliferative retinal tumor |
|||||||||||||||||||
neovascular |
|
|
|
|
|
|
|
|
293, 364 |
|
|
|
|
|
|
|
|
766 |
|
|
|
|
|
|
|
|||
– disease |
444 |
|
|
|
|
|
|
– retinal vascular disease 205 |
|
– vascular thrombosis |
243 |
|
|
|||||||||||||||
– glaucoma |
218, 337, 447, 561, 582, |
oral aphtous ulcer |
635 |
|
|
photosensitizer |
240, 241, 243 |
|
||||||||||||||||||||
583, 767 |
|
|
|
|
|
|
|
|
oxidative stress |
110, 307 |
|
|
photothrombosis |
243 |
|
|
||||||||||||
neovascularization |
131, 583, 703 |
oxygen 393 |
|
|
|
|
|
|
|
PHPV, see persistent hyperplastic |
||||||||||||||||||
– Eales‘ disease |
613 |
|
|
|
|
– oxygen-induced retinopathy |
35 |
primary vitreous phtocoagulation |
||||||||||||||||||||
– of the iris |
510 |
|
|
|
|
|
|
– supplementation |
132 |
|
|
332 |
|
|
|
|
|
|
|
|||||||||
nepafenac |
309 |
|
|
|
|
|
|
p53 |
128 |
|
|
|
|
|
|
|
|
PI-3 kinase |
|
124 |
|
|
|
|
|
|||
netrin |
51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PI3K-AKT-mTOR pathway |
124 |
|||||||||
neurodegeneration |
108 |
|
|
|
PAF |
127 |
|
|
|
|
|
|
|
|
pigment epithelial proliferation |
528, |
||||||||||||
neurofibromatosis |
741 |
|
|
|
|
PAN, see polyarteritis nodosa |
|
530, 740 |
|
|
|
|
|
|
|
|||||||||||||
neuro-oculocutaneous syndrome |
761 |
panretinal |
|
|
|
|
|
|
|
|
pigment epithelium-derived factor |
|||||||||||||||||
neurosarcoidosis, elevated ACE |
663 |
– cryotherapy |
277 |
|
|
|
|
(PEDF) |
127, 183, 231, 246, 326, 414, |
|||||||||||||||||||
neurovascular degeneration |
108 |
– laser |
|
|
|
|
|
|
|
|
708 |
|
|
|
|
|
|
|
||||||||||
neutrophil |
99 |
|
|
|
|
|
|
|
– – coagulation |
232 |
|
|
|
PIH, see pregnancy-induced hyperten- |
||||||||||||||
NF- B, see nuclear factor- |
B |
|
– – photocoagulation |
611 |
|
|
sion |
|
|
|
|
|
|
|
||||||||||||||
nitric oxide (NO) |
|
99, 113, 307 |
|
– photocoagulation (PRP) |
216, 275, |
pinocytosis |
|
140 |
|
|
|
|
|
|||||||||||||||
– synthase 2 |
47, 123 |
|
|
|
|
346, 525 |
|
|
|
|
|
|
|
|
PKC, see protein kinase C |
|
|
|||||||||||
NO, see nitric oxide |
|
|
|
|
|
Par6/Par3/atypical PKC (aPKC) polarity |
placental growth factor (PlGF) |
694 |
||||||||||||||||||||
nodular gliovascular proliferation 766 |
complex |
|
144 |
|
|
|
|
|
plasminogen activator inhibitor-1 |
|||||||||||||||||||
nonenzymatic glycation |
307 |
|
paracellular flux |
140 |
|
|
(PAI-1) |
637 |
|
|
|
|
|
|||||||||||||||
non-proliferative |
|
|
|
|
|
|
parafoveal retinal teleangiectasis |
251 |
plasticity |
81, 90 |
|
|
|
|
|
|||||||||||||
– changes |
700 |
|
|
|
|
|
|
paraproteinemia |
484 |
|
|
platelet-derived growth factor |
|
|||||||||||||||
– diabetic retinopathy (NPDR) |
344 |
paroxysmal hemoglobinuria |
484 |
(PDGF) |
34 |
|
|
|
|
|
||||||||||||||||||
– – 4-2-1 rule |
344 |
|
|
|
|
|
PARP inhibitor |
311 |
|
|
|
pluripotent cells |
183 |
|
|
|
||||||||||||
nonsteroidal anti-inflammatory drugs |
pars plana vitrectomy (PPV) |
268, 277, |
plus disease |
404, 406, 408 |
|
|
||||||||||||||||||||||
678 |
|
|
|
|
|
|
|
|
|
|
367, 494, 577, 623, 763 |
|
|
polyarteritis nodosa (PAN) |
668 |
|||||||||||||
non-viral gene transfer |
179 |
|
|
partial thromboplastin time (PPT) 433 |
polycythemia |
484 |
|
|
|
|
||||||||||||||||||
Norrie‘s disease |
186, 413, 571 |
|
PDGF, see platelet-derived growth factor |
polymyxin B |
285 |
|
|
|
|
|||||||||||||||||||
Norrin |
186, 571 |
|
|
|
|
|
|
PDR, see proliferative diabetic retinopa- |
posterior |
|
|
|
|
|
|
|
||||||||||||
– protein |
|
186 |
|
|
|
|
|
|
thy |
|
|
|
|
|
|
|
|
|
– hyaloid |
422, 599 |
|
|
|
|
||||
Notch receptor |
44 |
|
|
|
|
|
PDT, see photodynamic therapy |
|
– vitreous detachment (PVD) |
213 |
||||||||||||||||||
NPDR, see non-proliferative diabetic |
peak systolic flow velocity (PSV) |
170 |
povidone-iodine |
284 |
|
|
|
|||||||||||||||||||||
retinopathy |
|
|
|
|
|
|
|
pegaptanib |
|
69, 280, 366, 377, 380 |
PPT, see partial thromboplastin time |
|||||||||||||||||
nuclear factor- |
B (NF- |
B) |
|
98, 124, |
– sodium |
283 |
|
|
|
|
|
pre-corneal lens |
348 |
|
|
|
||||||||||||
232, 636 |
|
|
|
|
|
|
|
|
pentoxifyllin |
|
485 |
|
|
|
|
prednisolone |
622 |
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
perfluorhexyloctane (F6H8) |
264 |
preeclampsia |
691 |
|
|
|
|
||||||||||
occludin |
|
53, 109, 145, 653 |
|
|
|
perfluorocarbon |
|
|
|
|
|
pregnancy |
|
|
|
|
|
|
|
|||||||||
occlusion |
583 |
|
|
|
|
|
|
– gas |
263 |
|
|
|
|
|
|
|
|
– fluorescein angiography |
696 |
|||||||||
776 Subject Index
– pregnancy-induced hypertension |
relative afferent pupillary defect |
|
– of prematurity (ROP) |
55, 75, 78, |
||||||||||||||||||||||||
|
(PIH) |
691 |
|
|
|
|
|
(RAPD) |
|
452, 510 |
|
|
|
|
126, 180, 258, 392, 403, 404, 532, 567, |
|||||||||||||
– – arteriolar narrowing |
|
|
|
remodeling |
46 |
|
|
|
|
|
575, 724 |
|
|
|
|
|
|
|
|
|||||||||
premacular hemorrhage |
551 |
|
respiratory distress syndrome (RDS) |
– – laser intervention |
418 |
|
||||||||||||||||||||||
preretinal |
|
|
|
|
|
|
|
411 |
|
|
|
|
|
|
|
|
– – LIGHT-ROP study |
411 |
|
|||||||||
– hemorrhage |
550 |
|
|
|
|
reticulocyte |
705 |
|
|
|
|
– – mouse model |
393 |
|
|
|
||||||||||||
– neovascularization |
88, 742 |
|
retinal |
|
|
|
|
|
|
|
|
– – stage 4A |
418 |
|
|
|
|
|
||||||||||
pre-threshold |
403 |
|
|
|
|
– angioma |
249, 739 |
|
|
|
– – stage 4B (macula-off) |
419 |
||||||||||||||||
proliferative |
|
|
|
|
|
|
– angiomatous proliferation 744 |
– – stage 5 (total) retinal detachment |
||||||||||||||||||||
– diabetic retinopathy (PDR) |
70, 75, |
– arterial macroaneurysm (RAM) |
|
419 |
|
|
|
|
|
|
|
|
|
|
||||||||||||||
|
78, 228, 330 |
|
|
|
|
|
543, 751 |
|
|
|
|
|
|
|
– – surgical management |
418 |
||||||||||||
– – laser coagulation |
342 |
|
|
– arterial occlusion |
507 |
|
|
– – vascular endothelial growth fac- |
||||||||||||||||||||
– retinopathy |
396, 611 |
|
|
|
– capillary hemangioma (RCH) |
248, |
tor |
|
393 |
|
|
|
|
|
|
|
||||||||||||
– sickle retinopathy (PSR) |
718, 719, |
749 |
|
|
|
|
|
|
|
|
– oxygen-induced |
35 |
|
|
|
|||||||||||||
|
726 |
|
|
|
|
|
|
|
– detachment |
|
218, 392, 393, 403, 405, |
– proliferative diabetic |
|
78 |
|
|||||||||||||
– |
vitreoretinopathy (PVR) |
256, 595, |
412, 418, 421, 544, 598, 675, 709, 719, |
retinopexy |
228 |
|
|
|
|
|
|
|||||||||||||||||
|
598 |
|
|
|
|
|
|
|
727, 740, 766 |
|
|
|
|
|
|
retinoschisis |
214 |
|
|
|
|
|||||||
– – severe progressive form |
331 |
– – rhegmatogenous |
422 |
|
|
retinotomy |
577 |
|
|
|
|
|
|
|||||||||||||||
protein C |
436, 637 |
|
|
|
|
– endovascular surgery (REVL) |
495 |
retrobulbar anesthesia |
348 |
|
||||||||||||||||||
– |
deficiency |
|
509 |
|
|
|
|
– ganglion cell (RGC) |
188 |
|
|
retrolental fibroplasia (RLF) |
392, 403 |
|||||||||||||||
– resistance |
425, 432, 432 |
|
|
– hemorrhage |
|
629, 688 |
|
|
retrovirus |
177 |
|
|
|
|
|
|
||||||||||||
protein kinase C (PKC) |
66, 70, 307, 356 |
– hypoxia |
|
22, 187 |
|
|
|
|
RGC, see retinal ganglion cell |
|
||||||||||||||||||
– |
I/II 317 |
|
|
|
|
|
|
– ischemia |
27, 131, 275, 564 |
|
rhegmatogenous retinal detachment |
|||||||||||||||||
– Diabetic Macular Edema Study 320 |
– ischemic disease |
258 |
|
|
422, 477, 573 |
|
|
|
|
|
|
|||||||||||||||||
– Diabetic Retinopathy Study |
320 |
– neovascularization |
476, 582, 653, |
rheological |
|
|
|
|
|
|
|
|
||||||||||||||||
– |
inhibitor |
310, 317 |
|
|
|
657, 675, 676, 694 |
|
|
|
|
– abnormalities |
|
485 |
|
|
|
||||||||||||
– isoforms |
318 |
|
|
|
|
– pigment epithelium/epithelial |
|
– treatment |
458 |
|
|
|
|
|||||||||||||||
protein S |
637 |
|
|
|
|
|
(RPE) |
12, 212, 230, 244, 247, 602 |
rheumatic disease |
675 |
|
|
||||||||||||||||
– deficiency |
|
509 |
|
|
|
|
– – cells |
364 |
|
|
|
|
|
|
Rheumatrex |
681 |
|
|
|
|
||||||||
prothrombin G20210A gene mutation |
– – detachment |
|
662 |
|
|
|
|
rhexis hemorrhage |
470 |
|
|
|||||||||||||||||
|
437 |
|
|
|
|
|
|
|
– – hyperplasia |
|
767 |
|
|
|
|
ridge |
405 |
|
|
|
|
|
|
|
|
|||
proton beam radiotherapy |
587 |
– – hyperplastic |
706 |
|
|
|
rifampicin |
622 |
|
|
|
|
|
|
||||||||||||||
PRP, see panretinal photocoagulation |
– racemose hemangioma |
751 |
|
rituximab |
632, 685 |
|
|
|
|
|||||||||||||||||||
pruning |
46 |
|
|
|
|
|
|
– revascularization |
381 |
|
|
RLF, see retrolental fibroplasia |
|
|||||||||||||||
P-selectin |
705 |
|
|
|
|
– telangiectasis |
561 |
|
|
|
RNA aptamer |
380 |
|
|
|
|
||||||||||||
PSR, see proliferative sickle retinopathy |
– thickness |
377 |
|
|
|
|
RON, see radial optic neurotomy |
|||||||||||||||||||||
Purtscher‘s retinopathy |
512, 592, 609 |
– – measurement 221 |
|
|
|
ROP, see retinopathy of prematurity |
||||||||||||||||||||||
PVD, see posterior vitreous detachment |
– vascular |
|
|
|
|
|
|
|
ROS, see reactive oxygen species |
|||||||||||||||||||
PVR, see proliferative vitreoretinopathy |
– development |
|
35, 393 |
|
|
Roth spot |
631 |
|
|
|
|
|
|
|||||||||||||||
pyridoxamine |
310 |
|
|
|
|
– –ischemia |
661 |
|
|
|
|
roxithromycin |
630 |
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
– – occlusion |
532, 661 |
|
|
|
RTKI, see receptor tyrosine kinase |
||||||||||||||
quinine |
18 |
|
|
|
|
|
|
– – tumors |
735 |
|
|
|
|
inhibitor |
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
– vascular disease |
|
|
|
|
RTP-801 |
128 |
|
|
|
|
|
|
|
||||||
racemose hemangioma |
743 |
|
– – blood flow |
|
173 |
|
|
|
|
rt-PA |
493, ETDRS |
494 |
|
|
||||||||||||||
radial optic neurotomy (RON) |
219, |
– – optical coherence tomography |
|
rubeosis |
767 |
|
|
|
|
|
|
|
||||||||||||||||
|
460 |
|
|
|
|
|
|
|
(OCT) |
|
205 |
|
|
|
|
|
– iridis |
408, 447, 537, 561, 582, 583, |
||||||||||
radiation |
|
|
|
|
|
|
|
– – photodynamic therapy |
239 |
|
621 |
|
|
|
|
|
|
|
|
|
|
|||||||
– retinopathy |
17, 20, 548, 583, 609 |
– – verteporfin |
|
248 |
|
|
|
|
rubeotic secondary glaucoma |
274 |
||||||||||||||||||
– vasculopathy 584 |
|
|
|
|
– – vitrectomy |
|
260 |
|
|
|
|
ruboxistaurin |
317, 318 |
|
|
|||||||||||||
radiotherapy |
|
582, 756 |
|
|
|
– vasculature |
|
6 |
|
|
|
|
– safety |
322 |
|
|
|
|
|
|
|
|||||||
Radner Reading Charts |
370 |
|
– vasculitis |
613, 640, 657, 669 |
|
– treatment-emergent adverse |
||||||||||||||||||||||
RAM, see retinal arterial macroaneu- |
– vasoocclusive disease |
181, 629 |
|
effects |
|
322 |
|
|
|
|
|
|
||||||||||||||||
|
rysm |
|
|
|
|
|
|
|
– vasoproliferative tumor |
739, 751 |
ruby laser |
228 |
|
|
|
|
|
|
||||||||||
ranibizumab |
|
283, 366, 386, 387 |
– vein |
|
|
|
|
|
|
|
|
ruthenium-106 |
583 |
|
|
|
||||||||||||
– safety |
389 |
|
|
|
|
|
– – occlusion |
210, 609 |
|
|
|
salicylate |
308 |
|
|
|
|
|
|
|||||||||
– visual acuity |
389 |
|
|
|
|
– – thrombosis |
|
475 |
|
|
|
|
|
|
|
|
|
|
||||||||||
RANTES |
98 |
|
|
|
|
|
– venous sheathing |
651 |
|
|
Salmon patches |
|
716 |
|
|
|
||||||||||||
RAPD, see relative afferent pupillary |
retinal-choroidal |
|
|
|
|
– hemorrhage |
706 |
|
|
|
|
|||||||||||||||||
|
defect |
|
|
|
|
|
|
|
– anastomosis |
|
744 |
|
|
|
|
Sandostatin LAR |
|
327 |
|
|
|
|||||||
R-cadherin |
31 |
|
|
|
|
– tumor |
20 |
|
|
|
|
|
|
– side effects |
328 |
|
|
|
|
|||||||||
RCH, see retinal capillary hemangioma |
retinectomy |
289 |
|
|
|
|
sarcoidosis |
604, 642, 653, 657, 673, |
||||||||||||||||||||
reacitve oxygen species (ROS) |
66, 121 |
retinitis pigmentosa |
766 |
|
|
676 |
|
|
|
|
|
|
|
|
|
|
||||||||||||
READ-1 Study |
387 |
|
|
|
|
retinoblastoma |
|
565 |
|
|
|
|
Sca-1 |
84 |
|
|
|
|
|
|
|
|
||||||
READ-2 Study |
390 |
|
|
|
|
retinopathy |
607 |
|
|
|
|
scatter laser photocoagulation |
497 |
|||||||||||||||
receptor tyrosine kinase |
73 |
|
– bone marrow transplant-associated |
Schaumann body |
657 |
|
|
|
||||||||||||||||||||
– |
inhibitor (RTKI) |
54 |
|
|
|
606 |
|
|
|
|
|
|
|
|
schisis cavity |
706 |
|
|
|
|
||||||||
recombinant tissue plasminogen activa- |
– hypertensive |
|
210, 630, 688 |
|
scleral buckling |
|
419 |
|
|
|
||||||||||||||||||
|
tor (rt-PA) |
|
485 |
|
|
|
|
– occlusive |
607 |
|
|
|
|
SCORE Study |
42 |
|
|
|
|
|||||||||
Subject Index 777
SDF-1, see stromal cell-derived factor |
superoxide |
|
|
|
|
|
|
|
|
tumor necrosis factor (TNF) |
653 |
||||||||||||||||||||
sea fan |
622, 707, 715 |
|
|
|
|
|
– |
anion |
242 |
|
|
|
|
|
|
– |
(TNF- |
) |
47, 98, 129, 307, 357, |
||||||||||||
secondary glaucoma |
413, 663 |
|
|
|
– dismutase (SOD) |
127 |
|
|
|
|
636, 684, 705 |
|
|
|
|
|
|||||||||||||||
self-renewal capacity |
80, 90 |
|
|
|
suprachoridal seton implantation |
280 |
– – antagonists |
643 |
|
|
|
||||||||||||||||||||
serine/threonine kinase 317 |
|
|
|
sustained moderate vision loss |
|
TUNEL, see terminal dUTP nick end |
|||||||||||||||||||||||||
serous retinal detachment (SRD) |
212, |
|
(SMVL) |
321 |
|
|
|
|
|
|
labelling |
|
|
|
|
|
|
|
|||||||||||||
602, 662, 669, 694 |
|
|
|
|
|
synaptophysin |
113 |
|
|
|
|
tunica vasculosa lentis |
408 |
|
|
||||||||||||||||
serum angiotensin converting |
|
|
|
systemic |
|
|
|
|
|
|
|
|
|
tyrosine kinase |
307 |
|
|
|
|||||||||||||
enzyme |
663 |
|
|
|
|
|
|
– corticosteroids |
653 |
|
|
|
ultrasonography |
753 |
|
|
|
||||||||||||||
severe |
|
|
|
|
|
|
|
|
|
|
– immunosuppression |
|
|
|
|
|
|
||||||||||||||
– combined immunodeficiency syn- |
– – in rheumatic diseases |
675 |
|
uveal vascular system |
167 |
|
|
||||||||||||||||||||||||
drome (SCID) |
175 |
|
|
|
|
– lupus erythematosus (SLE) |
430, |
uveitis |
270, 653 |
|
|
|
|
||||||||||||||||||
– neovascular disease |
444 |
|
|
|
|
509, 592, 604, 620, 628, 676 |
|
|
– white-dot syndromes 677 |
|
|
||||||||||||||||||||
– progressive proliferative retinopa- |
– – retinopathy |
|
623, 630 |
|
|
|
VAMP2 |
113 |
|
|
|
|
|
||||||||||||||||||
thy 331 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
sheathotomy |
219 |
|
|
|
|
|
|
T cell, autoreactive |
630 |
|
|
|
vascular |
|
|
|
|
|
|
|
|
||||||||||
sickle |
|
|
|
|
|
|
|
|
|
|
tacrolimus (FK-506) |
643, 680 |
|
– development |
|
|
|
|
|
||||||||||||
– cell |
|
|
|
|
|
|
|
|
|
|
Takayasu disease |
676 |
|
|
|
– – ephrins |
74 |
|
|
|
|
|
|||||||||
– retinopathy |
|
432, 700, 751 |
|
|
|
TBI, see total body irradiation |
|
– – hematopoietic stem cells |
78 |
|
|||||||||||||||||||||
– – disease |
510, 620, 712, 713 |
|
|
|
telangiectasia |
607, 608, 718 |
|
|
– |
dysfunction |
108 |
|
|
|
|||||||||||||||||
– erythrocyte |
|
710 |
|
|
|
|
|
temporal arteritis 513 |
|
|
|
– endothelial growth factor (VEGF) |
|||||||||||||||||||
– retinopathy |
|
744 |
|
|
|
|
|
terminal dUTP nick end labelling |
|
|
3, 30, 357 |
|
|
|
|
|
|
||||||||||||||
silicone |
339 |
|
|
|
|
|
|
|
|
|
(TUNEL) |
114 |
|
|
|
|
– – retinopathy of prematurity |
|
|
||||||||||||
– oil |
|
|
|
|
|
|
|
|
|
|
Terson syndrome |
595 |
|
|
|
|
(ROP) |
393 |
|
|
|
|
|
||||||||
– – endotamponade |
277 |
|
|
|
|
tetradecapeptide |
324 |
|
|
|
– – inhibitor |
353 |
|
|
|
|
|||||||||||||||
– – tamponade |
265 |
|
|
|
|
|
thermotherapy |
|
582, 583 |
|
|
|
– – mRNA levels |
326 |
|
|
|
||||||||||||||
silver-wired vessel |
642 |
|
|
|
|
thrombocytopenia |
607 |
|
|
|
– – receptor-1 (VEGFR-1), see also |
||||||||||||||||||||
singlet oxygen |
|
242 |
|
|
|
|
|
thrombogenesis |
|
447 |
|
|
|
|
fms-like tyrosine kinase 1 (Flt-1) |
||||||||||||||||
sirolimus |
|
680 |
|
|
|
|
|
|
|
thrombolysis |
457, 515 |
|
|
|
|
42, 66 |
|
|
|
|
|
|
|
||||||||
SLE, see systemic lupus erythematosus |
thrombophilia |
445, 508 |
|
|
|
– – receptor-2 (VEGFR-2), see also fetal |
|||||||||||||||||||||||||
small peripheral hemangioma |
|
258 |
thrombosis |
|
428, 507 |
|
|
|
|
liver kinase 1 |
|
|
|
|
|
||||||||||||||||
smooth muscle cells |
25, 52 |
|
|
|
– |
risks |
483 |
|
|
|
|
|
|
|
|
(Flk-1) |
|
41, 66 |
|
|
|
|
|||||||||
SMVL, see sustained moderate vision |
thrombospondin |
|
|
|
|
|
– – VEGF164/165 |
377 |
|
|
|||||||||||||||||||||
loss |
|
|
|
|
|
|
|
|
|
|
– 1 (TSP-1) |
47, 50 |
|
|
|
|
– hamartoma 761 |
|
|
|
|||||||||||
SNAP-25 |
113 |
|
|
|
|
|
|
|
– 2 (TSP2) |
86 |
|
|
|
|
|
|
– heterogeneity |
25 |
|
|
|
||||||||||
snowballs |
642 |
|
|
|
|
|
|
thrombotic thrombocytopenic purpura |
– ischemia |
613 |
|
|
|
|
|||||||||||||||||
– opacitiy |
660 |
|
|
|
|
|
|
|
(TTP) |
602 |
|
|
|
|
|
|
– leakage |
607, 675 |
|
|
|
||||||||||
SOD, see superoxide dismutase |
|
|
|
Thy1.YFP mice |
|
113 |
|
|
|
|
– permeability |
356, 394, 694 |
|
|
|||||||||||||||||
sodium iodate |
|
159 |
|
|
|
|
|
Tie2-angiopoietin system |
82 |
|
|
– permeability factor (VFP) |
163 |
||||||||||||||||||
soft exudate |
292 |
|
|
|
|
|
|
tight junction |
|
25, 46, 141, 378 |
|
– |
permeability factor (VPF) |
66 |
|
||||||||||||||||
soluble RAGE |
|
311 |
|
|
|
|
|
– formation |
139 |
|
|
|
|
– progenitor cell |
41 |
|
|
|
|||||||||||||
somatostatin |
|
664 |
|
|
|
|
|
TNF- , see tumor necrosis factor |
|
– resistance |
167 |
|
|
|
|
||||||||||||||||
– analogue |
324 |
|
|
|
|
|
|
total body irradiation (TBI) |
606 |
|
– sheathing |
675 |
|
|
|
|
|||||||||||||||
– receptor subtypes (SSTR1 – 5) |
|
325 |
toxoplasma |
|
620 |
|
|
|
|
|
– smooth muscle cells (VSMC) |
14 |
|||||||||||||||||||
Sorafenib |
54 |
|
|
|
|
|
|
|
|
toxoplasmosis |
677, 766 |
|
|
|
– |
tortuosity |
741 |
|
|
|
|
||||||||||
sprouting |
46 |
|
|
|
|
|
|
|
|
trabeculectomy |
|
277 |
|
|
|
vasculitis |
507, 650, 653 |
|
|
||||||||||||
SRD, see serous retinal detachment |
traction retinal detachment 619 |
|
vasculogenesis |
24, 29, 40, 41, 78 |
|||||||||||||||||||||||||||
staining |
203, 528 |
|
|
|
|
|
|
tractional detachment 739 |
|
|
vasculopathy |
|
|
|
|
|
|
||||||||||||||
standardized change in macular thick- |
– rhegmatogenic retinal |
331 |
|
– after phototherapy |
588 |
|
|
||||||||||||||||||||||||
ness (CSMT) |
359, 363 |
|
|
|
|
transcellular flux |
140 |
|
|
|
– |
afterlocal resection |
589 |
|
|
||||||||||||||||
Starling‘s law |
|
142 |
|
|
|
|
|
transdifferentiation |
81 |
|
|
|
vaso-occlusive event |
713 |
|
|
|||||||||||||||
stereoscopic fundus photography |
291 |
transforming growth factor (TGF) |
68 |
vasoproliferative retinal tumor |
251, |
||||||||||||||||||||||||||
steroid response |
660 |
|
|
|
|
|
– |
(TGF- |
) |
47, 82, 706 |
|
|
|
|
751, 766 |
|
|
|
|
|
|
|
|||||||||
strabismus |
412 |
|
|
|
|
|
|
transpupillary thermotherapy |
582, |
VCAM-1 |
|
129, 705 |
|
|
|
|
|||||||||||||||
streptozotcin |
|
305 |
|
|
|
|
|
|
583 |
|
|
|
|
|
|
|
|
|
VE-cadherin |
53, 653 |
|
|
|
||||||||
stroma-derived factor-1 (SDF-1) |
|
43, |
transscleral cyclophotocoagulation |
|
VEGF, see vascular endothelial growth |
||||||||||||||||||||||||||
83, 98 |
|
|
|
|
|
|
|
|
|
|
|
278 |
|
|
|
|
|
|
|
|
|
|
factor |
|
|
|
|
|
|
|
|
subarachnoid hemorrhage |
595 |
|
|
trauma |
445 |
|
|
|
|
|
|
|
vein occlusion |
74 |
|
|
|
|
|||||||||||||
subclinical retinal thickening |
360 |
triamcinolone |
280, 331, 353, 365, 459, |
venous |
|
|
|
|
|
|
|
|
|||||||||||||||||||
subdural hemorrhage |
595 |
|
|
|
|
491 |
|
|
|
|
|
|
|
|
|
– beading |
293, 299 |
|
|
|
|||||||||||
subhyaloidal hemorrhage |
610 |
|
|
|
– acetonide |
161 |
|
|
|
|
– occlusive disease |
194 |
|
|
|||||||||||||||||
submacular hemorrhage |
551 |
|
|
|
trypsin |
15, 19, 523 |
|
|
|
|
– overcrossing |
470 |
|
|
|
||||||||||||||||
subretinal neovascularization |
530 |
– |
digest retinae |
|
113 |
|
|
|
– |
pressure |
|
167 |
|
|
|
|
|
||||||||||||||
subthreshold laser coagulation |
|
234 |
TSP-1, see thrombospondin 1 |
47 |
|
– sclerosis |
|
651 |
|
|
|
|
|
||||||||||||||||||
sulfur hexafluoride 263 |
|
|
|
|
tumor |
|
|
|
|
|
|
|
|
|
– sheathing |
293 |
|
|
|
|
|||||||||||
superficial plexus |
26 |
|
|
|
|
|
– |
glial |
21 |
|
|
|
|
|
|
|
|
– |
stasis retinopathy |
443, 519 |
|
|
|||||||||
superluminescent diode (SLD) |
|
222 |
– neuronal |
|
21 |
|
|
|
|
|
|
VEP, see visual evoked potential |
|
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
– |
retinal-choroidal |
20 |
|
|
|
verteporfin |
239, 244, 247 |
|
|
|||||||||||
778 Subject Index
vessel |
|
|
|
|
– lens-sparing |
419 |
|
Vogt-Koyanagi-Harada disease 677 |
||||
– cannulation |
494 |
|
– open sky |
422 |
|
Volk modified AVI system |
261 |
|||||
– closure |
614 |
|
|
– pars plana |
|
268, 277, 367, 494, 577, |
von Hippel-Lindau disease (VHL) |
|||||
– silver-wired |
642 |
|
623, 763 |
|
|
|
124, 248, 538, 749 |
|
||||
VFP, see vitreous fluorophotometry |
vitreomacular traction |
209 |
– HIF pathway |
134 |
|
|||||||
VHL, see von Hippel-Lindau disease |
vitreoretinal surgery |
728 |
VPF, see vascular permeability factor |
|||||||||
Virchow‘s triad |
485 |
|
vitreous |
|
|
|
|
Wegener granulomatosis 509, 668, |
||||
viscosity |
264 |
|
|
– base |
599 |
|
|
|
||||
visual |
|
|
|
|
– bleeding |
448 |
|
670, 676 |
|
|
||
– acuity (VA) |
363, 467, 478 |
– detachment |
334 |
|
white-dot uveitis syndrome |
677 |
||||||
– loss |
520 |
|
|
– fluorophotometry (VFP) 155 |
wide-angle viewing system |
331 |
||||||
visually evoked potential (VEP) 418 |
– hemorrhage |
160 |
|
Wnt pathway |
186, 571 |
|
||||||
vitamin E |
411 |
|
|
– hemorrhage |
218, 330, 331, 572, 595, |
Wyburn-Mason syndrome |
535, 743 |
|||||
vitreal hemorrhage |
413 |
609, 613,652, 708, 719, 727, 742, 763, |
xenon coagulation 228 |
|
||||||||
vitrectomy |
260, 349, 599 |
767 |
|
|
|
|
|
|||||
– 25-gauge system |
261 |
– traction |
737 |
|
zonula occludens-1 (ZO-1) |
109, 144 |
||||||
– early |
267 |
|
|
vitritis |
607, 650 |
|
||||||